Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exubera vs Subcutaneous Insulin in Type 2 Diabetes
NCT00136916Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Jun 2002
- Primary completion
- Dec 2008
- Modality
- Biologic
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of insulin human in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Pfizer. Primary endpoints: Change From Month 3 in Forced Expiratory Volume in 1 Second (FEV1) at Month 60, Change From Baseline in FEV1 and 5 more. Started Jun 2002; status: terminated.
02
Drugs
insulin human
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00136916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00136916.